<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Brighton, Timothy</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ASPIRE: Using Aspirin to Prevent Recurrence of VTE</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Venous thrombosis, which manifests mainly as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and serious disorder; it occurs in 1 per 1000 individuals per year worldwide, and patients who suffer from DVT or PE are at risk of recurrent events [Rosendaal FR. PLoS Med 2012]. There is limited information on safe and effective long-term preventive strategies. This article discusses results from the Aspirin to Prevent Recurrent Venous Thromboembolism [ASPIRE; ACTRN12605000004662] trial.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>